We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.
We are studying a new treatment using regulatory T cells for liver transplant recipients to see if it is safe and allows them to stop taking tacrolimus. We also want to learn how it affects graft function and patients' quality of life.
We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.
We are investigating whether sterile allogeneic spongioflex® allografts can improve knee function in patients with incomplete meniscal loss. The study will also assess safety and patient satisfaction over several years.
We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.
We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.
We are testing a new combination of two immunotherapy drugs for patients with recurrent glioblastoma. The goal is to see if this approach improves treatment outcomes compared to standard options.
We are studying whether daily prescribed dextroamphetamine can help reduce illicit amphetamine use in adults with amphetamine and opioid dependencies. The trial also looks at its effects on mental health, physical health, and overall quality of life.
We are investigating how different doses of dobutamine affect heart performance in patients with wild-type transthyretin amyloid cardiomyopathy. The study also looks at the safety of this treatment.
We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.
We are investigating how a protein may affect people with treatment-resistant depression using advanced imaging. This study compares P-glycoprotein activity in those who do not respond to treatment with those who do.
We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.
We are studying a new medication to see how safe it is and how the body reacts to it in healthy adults. This research helps us understand its potential for future use in patients.
We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.
We are studying whether fluasterone can help control high blood sugar in adults with Cushing’s syndrome. The trial will also look at its safety and effects on weight and cholesterol levels.
We are studying a new treatment called riliprubart to see if it works better than the standard IVIg therapy for people with chronic inflammatory demyelinating polyneuropathy. The trial will evaluate its effects on disability, fatigue, and overall quality of life.
We are evaluating the safety and effectiveness of Furmonertinib for patients with non-small cell lung cancer who have specific EGFR or HER2 mutations. This study aims to see how well the drug works in treating this type of cancer.
We are testing a new type of T-cell therapy for children and young adults with relapsed or refractory T-cell leukemia or lymphoma. The study aims to find a safe dose and see how well it works.
We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.
We are evaluating a new treatment for early-stage non-squamous non-small cell lung cancer to see how it compares to Keytruda after surgery and chemotherapy. This study aims to understand if the new drug works similarly in the body.